Background: Variable rates of HER2 protein overexpression and gene amplification have been reported in advanced ovarian cancers (AOC). Trastuzumab, tested only as a single agent, has been shown to ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

The following is a summary of "Advances and challenges in targeted therapies for HER2-amplified colorectal cancer," published ...

IBI354 has demonstrated promising anti-tumor efficacy and favorable safety profiles across multiple solid tumors. It not only holds potential to deliver a new generation of ADC therapies characterized ...

Envision this possible future clinical scenario: a breast cancer patient and her physicians are deciding on the best possible ...

Dr. Mabel Mardones educates patients on breast cancer subtypes, as well as treatment options for those with ER-positive, HER2 ...

Intas Pharmaceuticals has received approval from the Subject Expert Committee (SEC), functioning under the Central Drugs ...

and ligand-independent activation of estrogen receptor and coactivators by overexpression and/or amplification of HER2 HR+/HER2+ breast tumors are too aggressive to benefit from single-agent ...

AbbVie’s telisotuzumab adizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this ...